ClinicalTrials.gg
Drug

Iparomlimab/Tuvonralimab clinical trials

Also written QL1706 and PSB205.

studies test it
119
open now
102
in phase 3
12
first study started
2019

How each study uses Iparomlimab/Tuvonralimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Iparomlimab/Tuvonralimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Iparomlimab and Tuvonralimab (QL1706)
10
QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
8
Iparomlimab and Tuvonralimab Injection (QL1706)
7
Iparomlimab/Tuvonralimab
6
QL1706 (Iparomlimab/Tuvonralimab)
4

Development codes

QL1706
43
PSB205
3

In one entry with another drug

Given together, or one or the other

QL1706 Plus Lenvatinib
2

Studies by the year they started

118 studies that test it; most in 2025 (64); 1 more planned to start later

Studies that test Iparomlimab/Tuvonralimab, by start year
YearStudies
20191
20201
20214
20228
20232
20245
202564
202633

Who runs them

Industry 22 · Other 97

Qilu Pharmaceutical Co., Ltd. (21) · Sun Yat-sen University (9) · Fudan University (8) · Tianjin Medical University Cancer Institute and Hospital (7) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Fujian Cancer Hospital (4) · Hebei Medical University Fourth Hospital (4) · Tongji Hospital (3)

Often tested with

Tested in the same studies.

Lenvatinib (10) · Bevacizumab (4) · Xelox (3) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Gemcitabine (2) · Fecal Microbiota Transplantation (2) · QLC5513 (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 40, 3 in phase 3

Studies that test Iparomlimab/Tuvonralimab, phase 3 first.

Studies

Open first, then newest update. How each study uses Iparomlimab/Tuvonralimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 119

See all 119 studies that test Iparomlimab/Tuvonralimab →

Given beside what is tested · 9 — Iparomlimab/Tuvonralimab is usual care or a partner of the new treatment